Orchard Therapeutics Inked A Deal With Kyowa Kirin To Be Acquired For $16.00/ADS In Cash Plus An Additional Contingent Value Right Of $1.00/ADS, Representing A Total Value Of About $477.6M
Portfolio Pulse from Benzinga Newsdesk
Kyowa Kirin, a Japan-based pharmaceutical company, has announced a definitive agreement to acquire Orchard Therapeutics for $16.00 per American Depositary Share (ADS) in cash, totaling approximately $387.4 million. Additionally, Orchard shareholders will hold a contingent value right (CVR) of $1.00 per ADS, potentially increasing the total value of the deal to $477.6 million if certain conditions are met.
October 05, 2023 | 7:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Orchard Therapeutics is to be acquired by Kyowa Kirin for $16.00 per ADS in cash, with an additional $1.00 per ADS contingent on certain conditions. This could potentially increase the total deal value to $477.6 million.
The acquisition of Orchard Therapeutics by Kyowa Kirin is a significant event that directly impacts the company. The deal price of $16.00 per ADS represents a direct valuation of the company, and the additional $1.00 per ADS contingent on certain conditions could further increase this valuation. This news is highly relevant and important for investors in Orchard Therapeutics, and the impact on the company's stock price is likely to be positive in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100